nrg1 fusion-driven tumors: biology, detection, and role of afatinib and other erbb-targeting agents
Published 1 year ago • 1.5K plays • Length 12:49Download video MP4
Download video MP3
Similar videos
-
1:18
dr. tolba on targeting nrg1 fusions with afatinib
-
4:03
phase i/ii trial of zenocutuzumab for tumors with nrg1 fusions
-
2:31
dr. duruisseaux on the incidence of nrg1 fusions in solid tumors
-
2:45
dr. liu on nrg1 fusions in oncology
-
9:16
behind the mystery: nrg1 fusions
-
9:42
the truth about bdnf
-
![bdnf | how to literally grow the size of your brain & improve your memory [einstein-like tips]](https://i.ytimg.com/vi/BdQ4Sv027Cc/mqdefault.jpg)
6:07
bdnf | how to literally grow the size of your brain & improve your memory [einstein-like tips]
-
8:29
supratherapeutic inr
-
9:27
post-hoc analysis of sequential afatinib and osimertinib in nsclc patients
-
1:59
dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
-
14:30
the detection of ntrk gene fusions in nsclc
-
11:53
insight 2: a phase ii study of tepotinib plus osimertinib in met-amplified nsclc
-
2:27
crinecerfont for pediatric congenital adrenal hyperplasia | nejm
-
1:20
(pro)renin receptor: an emerging biomarker and target for fighting cancer
-
4:27
entrectinib: a review in ntrk solid tumours and ros1 nsclc
-
1:14
dr. trombetta on recurrent nrg1 rearrangements in invasive mucinous adenocarcinoma
-
2:33
advocating for early ngs testing to identify trk fusion
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
2:17
meet electrophysiologist dr. anthony aizer
-
1:06
prana thoracic - medtech innovator 1 minute video